Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
- PMID: 8953045
- DOI: 10.1126/science.274.5295.2100
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
Abstract
Adipocyte differentiation is an important component of obesity and other metabolic diseases. This process is strongly inhibited by many mitogens and oncogenes. Several growth factors that inhibit fat cell differentiation caused mitogen-activated protein (MAP) kinase-mediated phosphorylation of the dominant adipogenic transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) and reduction of its transcriptional activity. Expression of PPARgamma with a nonphosphorylatable mutation at this site (serine-112) yielded cells with increased sensitivity to ligand-induced adipogenesis and resistance to inhibition of differentiation by mitogens. These results indicate that covalent modification of PPARgamma by serum and growth factors is a major regulator of the balance between cell growth and differentiation in the adipose cell lineage.
Similar articles
-
Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma.J Biol Chem. 1996 Dec 13;271(50):31771-4. doi: 10.1074/jbc.271.50.31771. J Biol Chem. 1996. PMID: 8943212
-
Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase.J Biol Chem. 1997 Apr 18;272(16):10811-6. doi: 10.1074/jbc.272.16.10811. J Biol Chem. 1997. PMID: 9099735
-
c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity.Endocrinology. 1999 Jan;140(1):392-7. doi: 10.1210/endo.140.1.6457. Endocrinology. 1999. PMID: 9886850
-
Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis.J Biol Chem. 1998 Nov 27;273(48):32111-20. doi: 10.1074/jbc.273.48.32111. J Biol Chem. 1998. PMID: 9822687
-
Genes and transcription factors, including nuclear receptors: methods of studying their interactions.J Lab Clin Med. 2002 Oct;140(4):215-27. doi: 10.1067/mlc.2002.127370. J Lab Clin Med. 2002. PMID: 12389019 Review. No abstract available.
Cited by
-
PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.Curr Diab Rep. 2021 Apr 18;21(6):18. doi: 10.1007/s11892-021-01385-5. Curr Diab Rep. 2021. PMID: 33866450 Review.
-
Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.Genes Chromosomes Cancer. 2012 Apr;51(4):313-27. doi: 10.1002/gcc.21917. Epub 2011 Dec 14. Genes Chromosomes Cancer. 2012. PMID: 22170698 Free PMC article.
-
Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm.EMBO Rep. 2004 Feb;5(2):142-7. doi: 10.1038/sj.embor.7400082. EMBO Rep. 2004. PMID: 14755307 Free PMC article. Review.
-
TAZ Is a Negative Regulator of PPARγ Activity in Adipocytes and TAZ Deletion Improves Insulin Sensitivity and Glucose Tolerance.Cell Metab. 2020 Jan 7;31(1):162-173.e5. doi: 10.1016/j.cmet.2019.10.003. Epub 2019 Nov 7. Cell Metab. 2020. PMID: 31708444 Free PMC article.
-
Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.Breast Cancer Res. 2005;7(5):R699-707. doi: 10.1186/bcr1276. Epub 2005 Jul 6. Breast Cancer Res. 2005. PMID: 16168115 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
